Celularity Makes Cenplacel-L Available Under Florida's New State Investigational Cell Therapy Law

Celularity's decision to deploy cenplacel-L under Florida's newly enacted physician-directed investigational use framework places GMP manufacturers and regulatory affairs teams at an unfamiliar intersection: state statute authorizing allogeneic cell therapy administration outside FDA approval pathways, while federal oversight of manufacturing and sourcing remains intact.

Effective July 1, 2025, Florida Statutes § 458.3245 and § 459.0127 permit licensed physicians to administer unapproved cell therapies within their scope of practice, subject to strict sourcing, manufacturing accreditation, and patient consent requirements. Celularity's FDA-registered, GMP-compliant facility and existing clinical-grade inventory of cenplacel-L, also designated PDA-001 and PDA-002 in prior clinical research, position the company to begin near-term physician-directed deployment without additional manufacturing scale-up.

The commercial channel runs through Fountain Life, a preventive health operator integrating advanced diagnostics and physician oversight into a longevity-focused care model. That structure is relevant for QA and regulatory leads: patient selection, informed consent documentation, and physician credentialing become the primary compliance controls in the absence of an IND or BLA framework. Celularity has described the arrangement as consistent with Florida law's safeguards, though the company has not disclosed how adverse event reporting or post-use data collection will be governed under the state pathway.

For manufacturing operations, the immediate read is straightforward: Celularity's existing GMP infrastructure and inventory are the enabling assets. The Florida framework does not relax manufacturing standards, sourcing and production must still satisfy the accreditation requirements written into the statute. That means batch release criteria, chain-of-custody documentation, and sterility assurance protocols carry the same weight they would under a federally regulated clinical trial, even though the distribution pathway differs materially.

The broader regulatory affairs implication is harder to resolve. Florida's framework is among the first state-level structures in the United States to authorize allogeneic cell therapy use outside traditional federal channels. If other states follow, manufacturers will need to assess whether a single GMP site and quality system can support divergent state-by-state compliance requirements alongside any concurrent federal development programs, a site-qualification and documentation burden that has not yet been stress-tested at scale.

Celularity has indicated the Fountain Life partnership is intended to generate early clinical experience and inform future development strategy, suggesting the company views this pathway as a data-generating mechanism as much as a commercial one.

How Celularity structures adverse event capture and post-use reporting under the Florida framework will be an early indicator of whether state-level investigational use can generate data credible enough to support subsequent federal regulatory submissions.

Source: Celularity via GlobeNewswire, June 4, 2026.